Haemonetics (NYSE:HAE) Receives “Strong-Buy” Rating from Raymond James

Raymond James reiterated their strong-buy rating on shares of Haemonetics (NYSE:HAE) in a research note released on Friday,Benzinga reports. The brokerage currently has a $115.00 price target on the medical instruments supplier’s stock, down from their prior price target of $120.00.

HAE has been the topic of a number of other research reports. JMP Securities dropped their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. Needham & Company LLC dropped their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday. Finally, Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $95.00 to $68.00 in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Stock Down 5.8 %

Shares of NYSE HAE opened at $59.34 on Friday. Haemonetics has a 52-week low of $59.09 and a 52-week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The stock has a market cap of $2.98 billion, a P/E ratio of 23.36, a P/E/G ratio of 0.98 and a beta of 0.39. The firm has a 50 day moving average price of $76.94 and a 200 day moving average price of $78.62.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts expect that Haemonetics will post 4.59 EPS for the current year.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its position in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC increased its holdings in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 1,826 shares during the last quarter. KBC Group NV raised its position in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in Haemonetics in the third quarter valued at $204,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.